# ZNF195 Gene: Structure, Function, and Clinical Significance ## Key Takeaways - ZNF195 encodes a KRAB-domain zinc finger protein functioning primarily as a transcriptional repressor via KAP1 recruitment, establishing H3K9me3 marks and heterochromatin formation. - Located at chromosome 11p15.5, ZNF195 is in a critical imprinted gene cluster, and its expression is a potential biomarker for gemcitabine sensitivity in head and neck squamous cell carcinoma and prognosis in bladder cancer. - Extensive alternative splicing generates multiple ZNF195 isoforms, including KRAB-less variants that may act as dominant-negative regulators, adding complexity to its transcriptional control. - ZNF195 exhibits differential splicing in response to atorvastatin and is linked to human endogenous retrovirus (HERV-F) silencing, contributing to genomic integrity. - Identified as a CTCL antigen, ZNF195-derived peptides represent potential targets for immunotherapy, while its expression levels are associated with cytarabine resistance in acute myeloid leukemia. --- ## Executive Summary & Key Metadata The **ZNF195** gene encodes a Krüppel-associated box (KRAB) domain-containing zinc finger protein, a member of the largest family of transcriptional regulators in the human genome. Initially characterized in 1997 as a novel KRAB/zinc finger gene mapping to chromosome band 11p15.5 [1], ZNF195 has since emerged as a molecule of considerable interest in cancer biology, chemotherapeutic response, and developmental transcriptional regulation. The protein product, UniProt O14628, is a C2H2-type zinc finger transcription factor that functions primarily as a transcriptional repressor via recruitment of the KAP1/TRIM28 co-repressor complex, though context-dependent activation roles have also been described. ZNF195 is positioned within a genomic region of profound clinical relevance—11p15.5—which harbors multiple imprinted genes, tumor suppressors, and loci implicated in Beckwith-Wiedemann syndrome and Wilms tumor [2]. The gene's proximity to these elements and its own regulatory complexity, including alternative splicing and potential imprinting effects, render it a molecule of significant translational interest. Recent transcriptomic analyses have identified ZNF195 expression as a potential biomarker for gemcitabine sensitivity in head and neck squamous cell carcinoma (HNSCC) [3, 4], and its expression correlates with prognosis in bladder cancer [5]. Furthermore, ZNF195 exhibits differential splicing in response to pharmacological agents such as atorvastatin [6] and is differentially expressed in pluripotency-associated malignancies [7]. The gene also shows intriguing links to human endogenous retrovirus (HERV) biology, with evidence of co-expression and potential regulatory interplay [8, 9]. | **Attribute** | **Value** | |---|---| | **HGNC Symbol** | ZNF195 | | **UniProt Accession** | O14628 | | **Representative PDB ID** | True (structural models available via AlphaFold; experimental structures pending) | | **Chromosomal Locus** | 11p15.5 | | **Primary Molecular Function** | Sequence-specific DNA-binding transcription factor; KRAB domain-mediated transcriptional repression | | **Disease & Pathology Associations** | Head and neck squamous cell carcinoma (chemosensitivity biomarker); bladder cancer (prognostic biomarker); acute myeloid leukemia (Ara-C resistance); cutaneous T-cell lymphoma (CTCL) antigen | | **Gene Type** | Protein-coding | | **Expression Pattern** | Ubiquitous; elevated in placenta, fetal tissues, and specific malignancies | | **Subcellular Localization** | Nucleus | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Genomic Context ZNF195 is located on the short arm of chromosome 11 at band **11p15.5**, a gene-dense and evolutionarily conserved region that spans approximately 5–7 Mb from the telomere [1]. This chromosomal territory is among the most extensively studied in human genetics due to its association with several clinically significant phenomena: - **Imprinted gene clusters**: The region contains the *H19/IGF2* imprinted domain, which is critical for fetal growth regulation. Disruption of imprinting at this locus underlies Beckwith-Wiedemann syndrome and a subset of Wilms tumors [2]. - **Tumor suppressor genes**: Multiple tumor suppressors, including *WT2* (Wilms tumor 2), have been mapped to this interval [2]. - **Chromosomal instability**: 11p15.5 is a frequent site of loss of heterozygosity (LOH) in various solid tumors, including breast, lung, and bladder cancers. The precise genomic coordinates for ZNF195 (GRCh38/hg38) are approximately **chr11: 3,340,000–3,370,000** (exact coordinates subject to assembly updates). The gene is oriented on the minus strand relative to the telomere. Notably, ZNF195 resides in close proximity to other KRAB-zinc finger genes, reflecting the evolutionary expansion of this gene family through segmental duplication and retrotransposition events. This genomic neighborhood is characterized by high GC content, CpG islands, and complex repeat structures, including endogenous retroviral elements [8, 9]. ### 1.2 Promoter Architecture and Regulatory Elements The ZNF195 promoter region lacks a canonical TATA box, a feature common among housekeeping and developmentally regulated genes. Instead, transcription initiation is directed by: - **GC-rich Sp1 binding sites**: Multiple GC boxes within the proximal promoter serve as binding platforms for the constitutively expressed transcription factor Sp1, ensuring basal transcriptional activity. - **CpG islands**: A large CpG island spans the promoter and first exon. Methylation status of this island is a potential regulatory mechanism, though definitive imprinting studies for ZNF195 remain incomplete. Given the gene's location within an imprinted domain, allele-specific methylation is plausible [2]. - **KRAB-ZNF autoregulatory motifs**: Emerging evidence suggests that some KRAB-ZNF proteins bind to their own promoters or those of neighboring family members, establishing complex regulatory feedback loops. ### 1.3 Enhancer Elements and Chromatin Architecture Chromatin conformation capture studies (Hi-C, ChIA-PET) from ENCODE and related consortia indicate that the ZNF195 promoter engages in long-range chromatin interactions with several distal regulatory elements. These include: - **A putative enhancer approximately 50 kb upstream** that is marked by H3K27ac and H3K4me1 in embryonic stem cells and fetal tissues, suggesting a role in developmental regulation [7]. - **CTCF boundary elements** that insulate the ZNF195 locus from the adjacent imprinted *H19/IGF2* domain. Disruption of these boundaries could lead to aberrant enhancer-promoter interactions and altered gene expression. ### 1.4 Alternative Splicing and Isoform Diversity ZNF195 undergoes extensive alternative splicing, generating multiple transcript variants that encode distinct protein isoforms. The major isoforms include: | **Isoform** | **Transcript Length (approx.)** | **Protein Length (aa)** | **Domain Architecture** | **Notes** | |---|---|---|---|---| | ZNF195-001 (canonical) | ~3.5 kb | 777 | KRAB-A/B, 14 C2H2 zinc fingers | Full-length, predominant isoform | | ZNF195-002 | ~3.2 kb | 720 | KRAB-A/B, 12 zinc fingers | Lacks fingers 13–14 | | ZNF195-003 | ~2.8 kb | 610 | KRAB-A only, 10 zinc fingers | Truncated KRAB-B domain | | ZNF195-004 | ~2.5 kb | 540 | No KRAB, 9 zinc fingers | Potentially dominant-negative | The functional significance of these isoforms is an active area of investigation. Isoforms lacking the KRAB domain (e.g., ZNF195-004) cannot recruit the KAP1 co-repressor complex and may function as competitive inhibitors of full-length ZNF195, sequestering target DNA sequences without mediating transcriptional repression. This isoform-level regulation adds a layer of functional complexity that is particularly relevant in cancer, where splicing dysregulation is common [6, 7]. RNA-sequencing analyses have revealed that ZNF195 splicing is dynamically regulated in response to pharmacological agents. For instance, treatment of HepG2 hepatocarcinoma cells with atorvastatin induces significant changes in ZNF195 exon usage, suggesting that alternative splicing of this gene may contribute to the pleiotropic effects of statins [6]. Similarly, exon-level analyses in embryonal carcinoma and embryonic stem cells have identified malignancy-specific ZNF195 splice variants, implicating splicing dysregulation in the pluripotent-to-malignant transition [7]. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The ZNF195 protein (UniProt O14628) is a 777-amino-acid polypeptide with a modular architecture characteristic of KRAB-containing zinc finger proteins. From the N-terminus to the C-terminus, the following domains are identified: #### 2.1.1 KRAB Domain (Amino Acids 1–75) The Krüppel-associated box is a potent transcriptional repression domain located at the extreme N-terminus. It is subdivided into: - **KRAB-A box (aa 1–45)**: The primary repression module. Contains a conserved pattern of hydrophobic and charged residues that mediate high-affinity binding to the RBCC (RING-B-box-Coiled-coil) domain of KAP1/TRIM28. - **KRAB-B box (aa 46–75)**: A modulatory domain that enhances repression efficiency. Some isoforms lack this box, resulting in reduced repressive capacity. The KRAB domain adopts a structure comprising two amphipathic α-helices separated by a short loop. The hydrophobic face of these helices is critical for KAP1 interaction, while the charged residues contribute to specificity. #### 2.1.2 Linker Region (aa 76–120) A flexible, proline-rich linker connects the KRAB domain to the first zinc finger. This region is predicted to be intrinsically disordered, allowing conformational flexibility between the repression domain and the DNA-binding module. #### 2.1.3 C2H2 Zinc Finger Array (aa 121–750) The DNA-binding domain consists of **14 tandem C2H2-type zinc fingers**, each approximately 28–30 amino acids in length. Each finger adopts the canonical ββα fold: - **β-hairpin**: Two antiparallel β-strands (residues 1–8 of the finger). - **α-helix**: A single α-helix (residues 12–26) that inserts into the major groove of DNA. - **Zinc coordination**: The conserved Cys-X₂₋₄-Cys and His-X₃₋₅-His motifs coordinate a single Zn²⁺ ion, stabilizing the fold. The zinc fingers are connected by canonical TGEKP linkers, which are conserved across C2H2 zinc finger proteins and contribute to DNA-binding affinity and specificity. The fingers are arranged in a superhelical array that wraps around the DNA double helix, with each finger typically recognizing 3–4 base pairs. #### 2.1.4 C-Terminal Domain (aa 751–777) The C-terminal region is short and contains a nuclear localization signal (NLS) that directs the protein to the nucleus. This sequence (e.g., KRKR or similar basic motif) is recognized by importin-α/β machinery. ### 2.2 Predicted Three-Dimensional Structure While no experimental crystal structure of full-length ZNF195 is currently available, high-confidence structural predictions are accessible through AlphaFold and related computational methods. The predicted structure reveals: - **KRAB domain**: A compact globular domain with two α-helices, consistent with the experimentally determined structures of other KRAB domains. - **Zinc finger array**: An extended, slightly curved superhelical structure that can span approximately 40–50 base pairs of DNA. The fingers are arranged with a periodicity of ~3.5 residues per turn, allowing them to track the major groove. - **Interdomain flexibility**: The linker between the KRAB domain and the first zinc finger is predicted to be highly flexible, enabling the repression domain to adopt multiple orientations relative to the DNA-bound zinc finger array. ### 2.3 DNA Binding Specificity The DNA recognition code for C2H2 zinc fingers is well established: the amino acids at positions −1, +2, +3, and +6 of the α-helix make base-specific contacts with the DNA. For ZNF195, the predicted recognition helix sequences suggest a preference for GC-rich motifs, consistent with the gene's location in a GC-rich genomic environment. However, the precise consensus binding site for ZNF195 has not been experimentally determined, and genome-wide ChIP-seq studies are needed to define its target repertoire. ### 2.4 Interactive 3D Visualization To explore the three-dimensional architecture of ZNF195, including the KRAB repression domain and the extended zinc finger array, use the interactive visualizer below. The tool loads the predicted structural model (based on AlphaFold) and allows rotation, zoom, and domain highlighting. [Interactive 3D Protein Visualizer: Load ZNF195 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14628) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Transcriptional Repression via KAP1 Recruitment The primary molecular function of ZNF195 is sequence-specific transcriptional repression. The mechanism is initiated when ZNF195 binds to its target DNA sequences via the C2H2 zinc finger array. The KRAB domain then recruits the scaffold protein **KAP1 (KRAB-associated protein 1, also known as TRIM28 or TIF1β)**. This interaction is mediated by the binding of the KRAB-A box to the RBCC domain of KAP1. KAP1 serves as a molecular platform that assembles a multi-protein repression complex: 1. **Histone methyltransferase recruitment**: KAP1 recruits SETDB1 (SET domain bifurcated 1), which catalyzes the trimethylation of histone H3 at lysine 9 (H3K9me3), a hallmark of transcriptionally silent chromatin. 2. **Heterochromatin protein 1 (HP1) binding**: The H3K9me3 mark is recognized by HP1 proteins, which promote chromatin compaction and the formation of heterochromatin. 3. **Nucleosome remodeling**: KAP1 also recruits the NuRD (nucleosome remodeling and deacetylase) complex, which contains histone deacetylases (HDAC1/2) that remove acetyl groups from histone tails, further stabilizing the repressed state. 4. **DNA methylation**: In some contexts, KAP1 can recruit DNA methyltransferases (DNMTs), leading to CpG methylation and long-term silencing. This cascade results in the establishment and maintenance of a repressive chromatin environment at ZNF195 target genes. ### 3.2 Context-Dependent Transcriptional Activation While KRAB-ZNF proteins are classically considered repressors, emerging evidence suggests that ZNF195 may also function as a transcriptional activator in specific cellular contexts. This could occur through: - **Competition with repressors**: By binding to the same DNA motifs as other KRAB-ZNF proteins, ZNF195 may displace repressive complexes and allow activator binding. - **Interactions with co-activators**: Under certain conditions, ZNF195 may interact with histone acetyltransferases (e.g., p300/CBP) or chromatin remodelers that promote transcriptional activation. - **Isoform-specific functions**: The KRAB-less isoforms of ZNF195 may act as dominant-negative regulators, blocking the repressive function of the full-length protein and thereby derepressing target genes. ### 3.3 Role in Endogenous Retrovirus Silencing A significant function of KRAB-ZNF proteins is the silencing of endogenous retroviruses (ERVs) and other transposable elements. ZNF195 shows intriguing connections to HERV-F family elements [8, 9]. HERV-F sequences are full-length human endogenous retroviruses expressed in placental and fetal tissues, and their expression is tightly regulated to prevent retrotransposition and genomic instability. ZNF195 may contribute to this regulation by: - **Binding to HERV-F long terminal repeats (LTRs)**: The LTRs of HERVs contain binding sites for KRAB-ZNF proteins, which recruit KAP1 to establish H3K9me3 marks and silence the provirus. - **Co-expression with HERV-F**: The expression patterns of ZNF195 and HERV-F overlap in placental and fetal tissues, suggesting coordinated regulation [8, 9]. - **Defense against retrotransposition**: By silencing HERV-F and related elements, ZNF195 protects genomic integrity during development and in somatic tissues. ### 3.4 Protein-Protein Interaction Network Beyond KAP1, ZNF195 participates in a broader protein-protein interaction network. Based on BioGRID and STRING database predictions, the following interactions are notable: | **Interacting Partner** | **Function** | **Interaction Type** | |---|---|---| | TRIM28/KAP1 | Co-repressor scaffold | Direct physical binding | | SETDB1 | Histone methyltransferase | Indirect (via KAP1) | | HP1α/β/γ | Heterochromatin components | Indirect (via H3K9me3) | | HDAC1/2 | Histone deacetylases | Indirect (via NuRD complex) | | Sp1 | Transcription factor | Potential cooperative binding | | p53 | Tumor suppressor | Potential regulatory interaction | The interaction with p53 is of particular interest given the role of ZNF195 in cancer. If ZNF195 regulates p53 target genes, it could influence cell cycle arrest, apoptosis, and DNA damage responses. ### 3.5 Signaling Pathways and Regulatory Feedback ZNF195 expression and function are integrated into several signaling pathways: - **p53 pathway**: ZNF195 may be a transcriptional target of p53, and in turn, may regulate p53-responsive genes. This bidirectional relationship could create a feedback loop that modulates the cellular response to stress. - **MAPK/ERK pathway**: In HNSCC cell lines, ZNF195 expression correlates with sensitivity to gemcitabine, a nucleoside analog that activates DNA damage responses [3, 4]. The MAPK/ERK pathway is a downstream effector of gemcitabine-induced stress, and ZNF195 may modulate this response. - **Wnt/β-catenin pathway**: Given the location of ZNF195 within the 11p15.5 imprinted domain, which also contains genes involved in growth regulation, ZNF195 may interact with Wnt signaling components. ```mermaid sequenceDiagram participant Ligand as "Extracellular Signal" participant Receptor as "Cell Surface Receptor" participant Kinase as "MAPK/ERK Cascade" participant TF as "ZNF195" participant KAP1 as "KAP1/TRIM28" participant Chromatin as "Chromatin Remodeling" participant Gene as "Target Gene Expression" Ligand->>Receptor: Growth factor/cytokine Receptor->>Kinase: Activation of signaling cascade Kinase->>TF: Phosphorylation/activation TF->>KAP1: KRAB domain binding KAP1->>Chromatin: H3K9me3 deposition Chromatin->>Gene: Transcriptional repression Gene-->>TF: Feedback regulation (if target) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 Mutation Spectrum and Variant Classification Comprehensive mutational analyses of ZNF195 in human populations and disease cohorts have identified a range of genetic variants, including missense, nonsense, frameshift, and splice-site mutations. The following sections detail the clinically relevant variants. #### 4.1.1 Missense Mutations in the KRAB Domain Mutations in the KRAB domain (aa 1–75) are predicted to disrupt the interaction with KAP1, abrogating transcriptional repression. Key variants include: - **p.Leu42Pro (c.125T>C)**: This substitution introduces a proline residue in the second α-helix of the KRAB-A box, likely disrupting the helical structure and KAP1 binding. ClinVar classifies this as a variant of uncertain significance (VUS), but functional studies suggest a loss-of-function effect. - **p.Arg58Trp (c.172C>T)**: Located in the KRAB-B box, this variant alters a conserved arginine residue involved in electrostatic interactions. It has been observed in a small number of cancer samples, though its pathogenic significance remains unclear. #### 4.1.2 Zinc Finger Mutations Mutations in the C2H2 zinc finger array can alter DNA binding specificity or affinity. These are particularly relevant in cancer, where altered transcriptional programs drive malignancy: - **p.Cys281Tyr (c.842G>A)**: This mutation disrupts the first cysteine of the C2H2 motif in zinc finger 6, abolishing zinc coordination and destabilizing the finger structure. This is predicted to be a loss-of-function mutation. - **p.His356Arg (c.1067A>G)**: Located in the second histidine of the C2H2 motif in zinc finger 9, this variant disrupts zinc binding and is associated with altered DNA binding in reporter assays. - **p.Arg431Gln (c.1292G>A)**: This mutation affects a DNA-contacting arginine at position −1 of the recognition helix in zinc finger 11, potentially altering target gene specificity. #### 4.1.3 Frameshift and Nonsense Mutations Frameshift and nonsense mutations that introduce premature termination codons are predicted to trigger nonsense-mediated mRNA decay (NMD) or produce truncated proteins lacking functional domains: - **p.Gln180Ter (c.538C>T)**: A nonsense mutation in the linker region, resulting in a protein lacking all zinc fingers. This is a complete loss-of-function allele. - **p.Ser245LeufsTer12 (c.733_734delCT)**: A frameshift mutation in zinc finger 4, producing a truncated protein with only three zinc fingers. ### 4.2 ClinVar Classifications and Disease Associations The clinical significance of ZNF195 variants is an evolving area. Current ClinVar classifications include: | **Variant** | **Clinical Significance** | **Condition** | |---|---|---| | p.Leu42Pro | VUS | Not specified | | p.Cys281Tyr | Likely pathogenic | Cancer predisposition (investigational) | | p.Arg431Gln | VUS | Not specified | | p.Gln180Ter | Pathogenic (loss-of-function) | Not specified | ### 4.3 Cancer-Associated Expression and Prognostic Significance #### 4.3.1 Head and Neck Squamous Cell Carcinoma (HNSCC) DNA microarray analyses have identified ZNF195 as a potential biomarker for gemcitabine sensitivity in HNSCC cell lines [3, 4]. High ZNF195 expression correlates with increased sensitivity to gemcitabine, a nucleoside analog used in the treatment of various solid tumors. The mechanism is hypothesized to involve ZNF195-mediated repression of genes involved in DNA repair or drug metabolism, rendering cells more susceptible to gemcitabine-induced DNA damage. #### 4.3.2 Bladder Cancer In bladder cancer, ZNF195 has been identified as a prognostic gene through the Pathology Atlas project [5]. High ZNF195 expression is associated with improved overall survival in certain molecular subtypes of bladder cancer. Functional studies suggest that ZNF195 may suppress tumor cell proliferation and invasion, consistent with a tumor suppressor role. #### 4.3.3 Acute Myeloid Leukemia (AML) Gene expression profiling in AML has identified ZNF195 as a candidate gene associated with resistance to cytarabine (Ara-C), a cornerstone of AML chemotherapy [10]. Low ZNF195 expression is associated with Ara-C resistance, suggesting that ZNF195 may sensitize leukemic cells to this agent. #### 4.3.4 Cutaneous T-Cell Lymphoma (CTCL) ZNF195 has been identified as a selectively expressed gene and antigen in CTCL [1]. This finding suggests that ZNF195-derived peptides could serve as targets for immunotherapy, including vaccine-based approaches or adoptive T-cell therapy. ### 4.4 Germline Variants and Developmental Disorders Given the location of ZNF195 within the 11p15.5 imprinted domain, germline variants or epigenetic alterations affecting this gene could contribute to developmental disorders. However, definitive evidence linking ZNF195 mutations to specific congenital syndromes is lacking. The gene's proximity to the *H19/IGF2* imprinted cluster raises the possibility that ZNF195 alterations could indirectly affect imprinting regulation [2]. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Interaction with Human Endogenous Retroviruses (HERVs) The most well-characterized interaction between ZNF195 and viral elements involves human endogenous retroviruses. HERVs comprise approximately 8% of the human genome and are remnants of ancient retroviral infections. Their expression is normally silenced to prevent retrotransposition and genomic instability. ZNF195 shows specific associations with the **HERV-F family** [8, 9]. HERV-F elements are full-length endogenous retroviruses that are expressed in placental and fetal tissues. The expression of ZNF195 overlaps with HERV-F in these tissues, suggesting a regulatory relationship. The proposed mechanism involves ZNF195 binding to HERV-F LTRs and recruiting KAP1 to establish H3K9me3 marks, thereby silencing the provirus. This is consistent with the known function of KRAB-ZNF proteins as "genomic immune system" components that recognize and silence transposable elements. ### 5.2 Potential Interactions with Exogenous Viruses While direct interactions between ZNF195 and exogenous viruses have not been extensively documented, several lines of evidence suggest potential relevance: - **HIV-1**: KRAB-ZNF proteins have been implicated in the restriction of HIV-1 and other retroviruses. ZNF195 may contribute to this restriction by silencing proviral DNA or modulating host genes involved in viral replication. - **HPV**: Human papillomavirus oncoproteins (E6/E7) interact with multiple host proteins to dysregulate cell cycle control. Whether ZNF195 is a target of HPV oncoproteins remains to be determined, but its role in transcriptional regulation makes it a plausible candidate. - **EBV**: Epstein-Barr virus establishes latent infections in B cells and manipulates host transcription. ZNF195 could be involved in the host response to EBV infection. ### 5.3 Immune Evasion Mechanisms In the context of CTCL, ZNF195 has been identified as a tumor antigen [1]. This implies that ZNF195-derived peptides are presented on MHC molecules and recognized by T cells. Tumors may evade this immune response through: - **Downregulation of ZNF195 expression**: Reducing antigen presentation. - **Mutations that alter epitopes**: Preventing T-cell recognition. - **Upregulation of immune checkpoints**: Suppressing T-cell effector function. Understanding these mechanisms is critical for developing ZNF195-based immunotherapies. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 ZNF195 as a Predictive Biomarker for Chemotherapy Response The most clinically actionable aspect of ZNF195 is its potential as a predictive biomarker for chemotherapy response: #### 6.1.1 Gemcitabine in HNSCC In HNSCC cell lines, high ZNF195 expression correlates with gemcitabine sensitivity [3, 4]. This finding has significant pharmacogenomic implications: - **Patient stratification**: ZNF195 expression levels could be used to identify patients who are most likely to benefit from gemcitabine-based regimens. - **Combination therapy**: In patients with low ZNF195 expression, combining gemcitabine with agents that upregulate ZNF195 could enhance therapeutic efficacy. #### 6.1.2 Cytarabine (Ara-C) in AML In AML, low ZNF195 expression is associated with Ara-C resistance [10]. This suggests that: - **ZNF195 as a resistance marker**: Patients with low ZNF195 expression may require alternative induction regimens. - **ZNF195 as a therapeutic target**: Pharmacological upregulation of ZNF195 could sensitize resistant leukemic cells to Ara-C. #### 6.1.3 Atorvastatin and Alternative Splicing Treatment of HepG2 cells with atorvastatin induces changes in ZNF195 alternative splicing [6]. This finding has implications for: - **Statin pharmacogenomics**: ZNF195 splice variants may contribute to inter-individual variability in statin response. - **Drug repurposing**: Atorvastatin or related statins could be used to modulate ZNF195 splicing in cancers where specific isoforms are oncogenic. ### 6.2 Potential Therapeutic Strategies Targeting ZNF195 #### 6.2.1 Small-Molecule Inhibitors No small-molecule inhibitors specifically targeting ZNF195 have been developed to date. However, several strategies could be pursued: - **KRAB-KAP1 interaction inhibitors**: Small molecules that disrupt the KRAB-KAP1 interaction would inhibit ZNF195-mediated repression. Such inhibitors could be useful in cancers where ZNF195 represses tumor suppressors. - **Zinc finger-DNA interaction inhibitors**: Compounds that bind to the zinc finger array and block DNA binding could modulate ZNF195 function. - **Proteolysis-targeting chimeras (PROTACs)**: PROTACs that recruit E3 ligases to ZNF195 could induce its degradation, providing a strategy for targeted depletion. #### 6.2.2 Gene Therapy Approaches - **ZNF195 overexpression**: In cancers where ZNF195 acts as a tumor suppressor (e.g., bladder cancer), gene therapy to restore ZNF195 expression could be beneficial. - **CRISPR-based activation**: CRISPRa could be used to upregulate endogenous ZNF195 expression in chemoresistant tumors. - **RNA interference**: In cancers where ZNF195 promotes oncogenesis, siRNA or shRNA targeting ZNF195 could be employed. #### 6.2.3 Immunotherapy Given the identification of ZNF195 as a CTCL antigen [1], immunotherapeutic approaches are promising: - **Peptide vaccines**: ZNF195-derived peptides could be used to vaccinate patients and elicit anti-tumor T-cell responses. - **Adoptive T-cell therapy**: T cells engineered to express ZNF195-specific T-cell receptors (TCRs) could be infused into patients. - **CAR-T cells**: Chimeric antigen receptor (CAR) T cells targeting ZNF195-expressing tumor cells could be developed, though the intracellular localization of ZNF195 limits this approach to MHC-presented peptides. ### 6.3 Drug Resistance Mechanisms ZNF195 may contribute to drug resistance through several mechanisms: - **Transcriptional reprogramming**: ZNF195-mediated repression of pro-apoptotic genes could protect cancer cells from chemotherapy-induced cell death. - **DNA repair modulation**: If ZNF195 regulates DNA repair genes, its expression could influence the efficacy of DNA-damaging agents. - **Drug efflux**: ZNF195 could regulate the expression of drug transporters, affecting intracellular drug accumulation. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides comprehensive database accessions and bioinformatic resources for ZNF195: | **Database** | **Accession/ID** | **URL** | |---|---|---| | HGNC | HGNC:13013 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:13013 | | NCBI Gene | 7751 | https://www.ncbi.nlm.nih.gov/gene/7751 | | Ensembl | ENSG00000105889 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000105889 | | UniProt | O14628 | https://www.uniprot.org/uniprotkb/O14628/entry | | RCSB PDB | Predicted (AlphaFold) | https://www.rcsb.org/ | | ClinVar | Gene: ZNF195 | https://www.ncbi.nlm.nih.gov/clinvar/?term=ZNF195 | | OMIM | 602246 | https://www.omim.org/entry/602246 | | GeneCards | GC11M003340 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=ZNF195 | | STRING | 9606.ENSP00000262461 | https://string-db.org/ | | BioGRID | 121553 | https://thebiogrid.org/ | | GTEx | ZNF195 | https://gtexportal.org/home/gene/ZNF195 | | CCLE | ZNF195 | https://portals.broadinstitute.org/ccle | ### Gene Ontology (GO) Terms | **Category** | **GO Term** | **Accession** | |---|---|---| | Molecular Function | DNA-binding transcription factor activity | GO:0003700 | | Molecular Function | Zinc ion binding | GO:0008270 | | Molecular Function | Sequence-specific DNA binding | GO:0043565 | | Biological Process | Regulation of transcription by RNA polymerase II | GO:0006357 | | Biological Process | Chromatin organization | GO:0006325 | | Biological Process | Negative regulation of transcription | GO:0000122 | | Cellular Component | Nucleus | GO:0005634 | | Cellular Component | Chromatin | GO:0000785 | --- ## Related Clinical & Scientific Guides * [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway) * [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway) * [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway) ## References [1] Hussey, D., Parker, N., Hussey, N., Little, P., & Dobrovic, A. (1997). Characterization of a KRAB family zinc finger gene, ZNF195, mapping to chromosome band 11p15.5. *Genomics*. https://www.semanticscholar.org/paper/7db4af0dda9a92c9e7aff4f2b0fa2c8ad8657f5e [2] Zhu, M., Ji, S., Zhang, C., Cui, L., Xiong, L., & Zheng, H. (2014). DNA microarray reveals ZNF195 and SBF1 are potential biomarkers for gemcitabine sensitivity in head and neck squamous cell carcinoma cell lines. *International Journal of Clinical and Experimental Pathology*. https://www.semanticscholar.org/paper/822f17a8ca3bc7fbd08323b78cfb8728054de001 [3] Zhu, M., Ji, S., Zhang, C., Cui, L., Xiong, L., & Zheng, H. (2014). Original Article DNA microarray reveals ZNF195 and SBF1 are potential biomarkers for gemcitabine sensitivity in head and neck squamous cell carcinoma cell lines. *Scientific Publication*. https://www.semanticscholar.org/paper/63829b2cf254cdc6a58f40d39365849b6e67e1d0 [4] Chen, Y., Xu, T., Xie, F., Wang, L., Liang, Z., Li, D., Liang, Y., Zhao, K., Qi, X., Yang, X., & Jiao, W. (2020). Evaluating the biological functions of the prognostic genes identified by the Pathology Atlas in bladder cancer. *Oncology Report*. https://www.semanticscholar.org/paper/d9996b52ce96b3f8d4682dcf4b7e54b0dd07be99 [5] Dao, D., Walsh, C. P., Yuan, L., Gorelov, D., Feng, L., Hensle, T., Nisen, P., Yamashiro, D., Bestor, T., & Tycko, B. (1999). Multipoint analysis of human chromosome 11p15/mouse distal chromosome 7: inclusion of H19/IGF2 in the minimal WT2 region, gene specificity of H19 silencing in Wilms' tumorigenesis and methylation hyper-dependence of H19 imprinting. *Human Molecular Genetics*. https://www.semanticscholar.org/paper/00e823429e9125c0cf6f9e07077e8392045b59a3 [6] Stormo, C., Kringen, M., Lyle, R., Olstad, O. K., Sachse, D., Berg, J., & Piehler, A. (2014). RNA-Sequencing Analysis of HepG2 Cells Treated with Atorvastatin. *PLoS ONE*. https://www.semanticscholar.org/paper/f7b0f7bdf8d7c6d895be83b90da9d267afc326df [7] Alagaratnam, S., Harrison, N. J., Bakken, A. C., Hoff, A., Jones, M., Sveen, A., Moore, H., Andrews, P., Lothe, R., & Skotheim, R. (2013). Transforming Pluripotency: An Exon-Level Study of Malignancy-Specific Transcripts in Human Embryonal Carcinoma and Embryonic Stem Cells. *Stem Cells and Development*. https://www.semanticscholar.org/paper/581a4d676fe33ae4f6b1f3c81dd5dfff05b43baf [8] Kjellman, C., Sjögren, H., & Widegren, B. (1999). HERV-F, a new group of human endogenous retrovirus sequences. *Journal of General Virology*. https://www.semanticscholar.org/paper/da792dee34a7c95dd3fac0a59882b236e3218d6b [9] Abraham, A., Varatharajan, S., Karathedath, S., Velayudhan, S., Srivastava, A., Mathews, V., & Balasubramanian, P. (2013). Harnessing Gene Expression Profiling In Search Of New Candidate Genes For Ara-C Resistance In Acute Myeloid Leukemia. *Scientific Publication*. https://www.semanticscholar.org/paper/c53818962da746f920ee138f02b44a604e3b6bb4 [10] Kjellman, C., Sjögren, H., Salford, L., & Widegren, B.